Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY: Sofosbuvir/Ledipasvir Combinations in Chronic HCV
NCT01805882Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sofosbuvir, ledipasvir, radalbuvir and vedroprevir in hepatitis C virus infection (9 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Sustained Viral Response 12 Weeks After Treatment. Started Jan 2013; status: completed.
02
Drugs
sofosbuvirledipasvirradalbuvirvedroprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01805882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01805882.